Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [225Ac]Ac-AKY-1189 (therapeutic)
Ac-AKY-1189 · 1 trial · 7 indications
• Dose-limiting toxicities (DLTs) is defined as any predefined AE occurring during the DLT observation period, except those that are clearly and incontrovertibly due to extraneous circumstances. The number of patients who experience a DLT in Part 1, will be reported by dose level.
• An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE in Part 1 will be reported.
• Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST 1.1, by tumor types.
| Arm | Type | Description |
|---|---|---|
| [225Ac]Ac-AKY-1189 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| [225Ac]Ac-AKY-1189 (therapeutic) | DRUG | \[225Ac\]Ac-AKY-1189 Injection |
| [64Cu]Cu-AKY-1189 (imaging) | DRUG | \[64Cu\]Cu-AKY-1189 Injection |
Inclusion Criteria: * Histologic or cytologic confirmation of locally advance or metastatic disease * Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1 * ECOG Performance Status of 0 or 1 * Adequate end-organ function * Ability to give informed consent and comply...
Ac-AKY-1189 is an investigational small molecule being developed for the treatment of urothelial carcinoma of the bladder. It is also being studied in other solid tumors including triple negative breast cancer, hormone receptor positive breast adenocarcinoma, non-small cell lung cancer, cervical adenocarcinoma, colorectal adenocarcinoma, and head and neck cancer.
Ac-AKY-1189 is a small molecule therapeutic agent. Its specific molecular target has not been disclosed in available information. The drug is being evaluated in a Phase 1 clinical trial for its safety and efficacy in patients with various solid tumors.
Ac-AKY-1189 is being developed by Aktis Oncology, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol AKTS. The drug is currently in Phase 1 clinical development.
Ac-AKY-1189 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received Fast Track designation from the FDA for its development program.
Ac-AKY-1189 is being studied in a Phase 1 clinical trial with the identifier NCT07020117. This trial is recruiting patients with solid tumors and has an estimated enrollment of 150 participants. The study is being conducted in the United States.
Yes, Ac-AKY-1189 is also known as [225Ac]Ac-AKY-1189, which is the therapeutic form of the drug. The compound is being investigated in clinical trials for its potential use in treating various solid tumors, including urothelial carcinoma of the bladder.